As filed with the Securities and Exchange Commission on March 29, 2016

Registration No. 333-          

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

EPIRUS BIOPHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

04-3514457

(State or Other Jurisdiction of
Incorporation or Organization)

 

(I.R.S. Employer
Identification No.)

 

699 Boylston Street

Eighth Floor

Boston, Massachusetts 02116

(Address of Principal Executive Offices) (Zip Code)

 

 

EPIRUS Biopharmaceuticals, Inc. 2015 Equity Incentive Plan

EPIRUS Biopharmaceuticals, Inc. 2015 Employee Stock Purchase Plan

(Full Title of the Plan)

 

 

Robert Ticktin, Esq.

Senior Vice President, General Counsel and Secretary

EPIRUS Biopharmaceuticals, Inc.

699 Boylston Street

Eighth Floor

Boston, Massachusetts 02116

(Name and Address of Agent for Service of Process)

 

(617) 600-3497

(Telephone Number, Including Area Code, of Agent For Service)

 

Copies to:

 

William C. Hicks, Esq.

Pamela B. Greene, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  o

 

Accelerated filer  x

 

 

 

Non-accelerated filer  o  (Do not check if a smaller
reporting company)

 

Smaller reporting company  o

 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

Title of Securities
to be Registered

 

Amount
to be
Registered(1)

 

Proposed
Maximum
Offering
Price
Per Share

 

Proposed
Maximum
Aggregate
Offering Price

 

Amount of
Registration Fee

 

Common Stock, $0.001 par value

 

975,102

(2)

$

2.83

(4)

$

2,759,528.66

(4)

$

277.89

 

Common Stock, $0.001 par value

 

120,000

(3)

$

2.83

(4)

$

339,600.00

(4)

$

34.20

 

(1)      Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock, par value $0.001 per share (“Common Stock”) of EPIRUS Biopharmaceuticals, Inc. (the “Company” or the “Registrant”) that become issuable under the EPIRUS Biopharmaceuticals, Inc. 2015 Equity Incentive Plan (the “2015 Plan”) and the EPIRUS Biopharmaceuticals, Inc. 2015 Employee Stock Purchase Plan (the “ESPP,” and together with the 2015 Plan, the “Plans”), by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant’s outstanding shares of Common Stock.

(2)      Represents the additional shares of Common Stock available for future issuance under the Registrant’s 2015 Plan resulting from an automatic annual increase as of January 1, 2016.

(3)      Represents the additional shares of Common Stock available for future issuance under the Registrant’s ESPP resulting from an automatic annual increase as of January 1, 2016.

(4)      Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h)(1) under the Securities Act. Pursuant to Rule 457(c) under the Securities Act, in the case of shares of Common Stock to be issued in connection with equity awards that have not yet been granted, the fee is calculated on the basis of the average of the high and low sale prices of the Common Stock of the Registrant reported on the NASDAQ Capital Market as of a date (March 22, 2016) within five business days prior to filing this Registration Statement.

 

 

 


 

EXPLANATORY NOTE

 

T his Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,095,102 shares of the Registrant’s common stock issuable under the following employee benefit plans for which a Registration Statement of the Registrant on Form S-8 (File No. 333-205418) is effective: (i) the EPIRUS Biopharmaceuticals, Inc. 2015 Equity Incentive Plan, as a result of the operation of an automatic annual increase provision therein, which added 975,102 shares of common stock, and (ii) the EPIRUS Biopharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 120,000 shares of common stock.

 

INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON

FORM S-8

 

Pursuant to Instruction E of Form S-8, the entire contents of the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on July 1, 2015 (File No. 333-205418) is incorporated by reference herein.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8. Exhibits.

 

The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part of this Registration Statement.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, the Commonwealth of Massachusetts, on this 29th day of March, 2016.

 

 

 

EPIRUS BIOPHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ Amit Munshi

 

Name:

Amit Munshi

 

Title:

President and Chief Executive Officer

 

3


 

POWER OF ATTORNEY AND SIGNATURES

 

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Amit Munshi, Thomas Shea and Robert Ticktin and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended, and all post-effective amendments thereto and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities below on the dates indicated.

 

Name

 

Title(s)

 

Date

 

 

 

 

 

/s/ Amit Munshi

 

President, Chief Executive Officer and Director

 

March 29, 2016

Amit Munshi

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Thomas Shea

 

Senior Vice President, Chief Financial Officer and

 

March 29, 2016

Thomas Shea

 

Treasurer (Principal Financial Officer and

 

 

 

 

Principal Accounting Officer)

 

 

 

 

 

 

 

/s/ Mark H.N. Corrigan, M.D.

 

Chairman of the Board and Director

 

March 29, 2016

Mark H.N. Corrigan, M.D.

 

 

 

 

 

 

 

 

 

/s/ J. Kevin Buchi

 

Director

 

March 29, 2016

J. Kevin Buchi

 

 

 

 

 

 

 

 

 

/s/ Geoffrey Duyk, M.D., Ph.D.

 

Director

 

March 29, 2016

Geoffrey Duyk, M.D., Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Daotian Fu, Ph.D.

 

Director

 

March 29, 2016

Daotian Fu, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ William Hunter, M.D.

 

Director

 

March 29, 2016

William Hunter, M.D.

 

 

 

 

 

 

 

 

 

/s/ Julie McHugh

 

Director

 

March 29, 2016

Julie McHugh

 

 

 

 

 

 

 

 

 

/s/ Scott Rocklage, Ph.D.

 

Director

 

March 29, 2016

Scott Rocklage, Ph.D.

 

 

 

 

 

4


 

INDEX TO EXHIBITS

 

Exhibit

 

 

No.

 

Description of Exhibit

 

 

 

4.1

 

Sixth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s registration statement on Form S-1/A filed on November 4, 2005) (File No. 333-121173)

 

 

 

4.2

 

Certificate of Amendment to the Registrant’s Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s current report filed on 8-K on December 21, 2009) (File No. 000-51171)

 

 

 

4.3

 

Certificate of Amendment to the Registrant’s Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s current report filed on 8-K on September 9, 2010) (File No. 000-51171)

 

 

 

4.4

 

Certificate of Amendment to the Registrant’s Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s current report filed on 8-K on October 2, 2013) (File No. 000-51171)

 

 

 

4.5

 

Certificate of Amendment to the Registrant’s Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s current report filed on 8-K on July 15, 2014) (File No. 000-51171)

 

 

 

4.6

 

Certificate of Amendment to the Registrant’s Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Registrant’s current report filed on 8-K on July 15, 2014) (File No. 000-51171)

 

 

 

4.7

 

Certificate of Amendment to the Registrant’s Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s current report filed on 8-K on June 9, 2015) (File No. 000-51171)

 

 

 

4.8

 

Amended and Restated By-Laws (incorporated by reference to Exhibit 3.01 to the Registrant’s current report on 8-K filed on July 18, 2014) (File No. 000-51171)

 

 

 

4.9

 

Specimen Certificate representing the Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant’s quarterly report on Form 10-Q filed on August 11, 2014) (File No. 000-51171)

 

 

 

*5.1

 

Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

 

 

 

*23.1

 

Consent of Ernst & Young LLP, the Registrant’s independent registered public accounting firm

 

 

 

*23.2

 

Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1 and incorporated herein by reference)

 

 

 

*24.1

 

Power of Attorney (included as part of the signature page to this Registration Statement)

 

 

 

99.1

 

EPIRUS Biopharmaceuticals, Inc. 2015 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registrant’s registration statement on Form S-8 filed on July 1, 2015) (File No. 333-205418)

 

 

 

99.2

 

EPIRUS Biopharmaceuticals, Inc. 2015 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.2 to the Registrant’s registration statement on Form S-8 filed on July 1, 2015) (File No. 333-205418)

 

* Filed herewith.

 

5

Grafico Azioni EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di EPIRUS Biopharmaceuticals (CE)
Grafico Azioni EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di EPIRUS Biopharmaceuticals (CE)